Economic Dimensions of Personalized and Precision Medicine

Ernst R. Berndt, Dana Goldman and John W. Rowe

in NBER Books from National Bureau of Economic Research, Inc

JEL-codes: I1 L1 O3 (search for similar items in EconPapers)
Date: 2019
Note: EH PR
References: Add references at CitEc
Citations: View citations in EconPapers (2)

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Chapters in this book:

Introduction to "Economic Dimensions of Personalized and Precision Medicine" , pp 1-7

Ernst R. Berndt, Dana Goldman and John W. Rowe

The Economic Value and Pricing of Personalized Medicine , pp 9-19

Tomas Philipson

Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS , pp 21-52

Manuel Hermosilla and Jorge Lemus

The Value of Pharmacogenomic Information , pp 53-86

John A. Graves, Zilu Zhou, Shawn Garbett and Josh F. Peterson

The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory , pp 87-114

Ernst R. Berndt and Mark R. Trusheim

Characterizing the Drug Development Pipeline for Precision Medicines , pp 115-157

Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern

Cost Sharing in Insurance Coverage for Precision Medicine , pp 159-184

Mark V. Pauly

Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments , pp 185-216

Kristopher Hult

Physicians’ Financial Incentives to Personalize Medicine , pp 217-235

David H. Howard, Jason Hockenberry and Guy David

Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan , pp 237-272

Jui-fen Rachel Lu, Karen Eggleston and Joseph Tung-Chieh Chang

The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger , pp 273-304

Rebecca A. Pulk, Jove Graham, Frank Lichtenberg, Daniel Maeng, Marc S. Williams and Eric Wright

Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies , pp 305-334

Philippe Gorry and Diego Useche

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nbr:nberbk:bern-13

Ordering information: This item can be ordered from
https://www.nber.org ... d-precision-medicine

Access Statistics for this book

More books in NBER Books from National Bureau of Economic Research, Inc National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.. Contact information at EDIRC.
Bibliographic data for series maintained by ().